No Data
No Data
In the DTx product business for the fiscal year ending June 2024, Sasmed will continue to promote the development of therapeutic applications.
On the 9th, Sasmeeed <4263> released its financial results for the fiscal year ending June 2024. Business revenue decreased by 35.4% compared to the previous period to 0.342 billion yen, operating loss was 0.364 billion yen (compared to a loss of 0.048 billion yen in the previous period), ordinary loss was 0.357 billion yen (compared to a loss of 0.044 billion yen in the same period), and net loss for the year was 0.357 billion yen (compared to a loss of 0.05 billion yen in the same period). The business revenue of the DTx product business was 0.2 billion yen (0.4 billion yen in the same period last year), and the segment profit was 0.055 billion yen (profit of 0.256 billion yen in the same period). Treatment.
Susmed: Financial results presentation materials for the period ending June 2024.
Susmed: Fiscal year ending June 2024, financial statement text (based on Japan standards) (non-consolidated)
McDonald's, Isetan Mitsukoshi, Rakuten G, ENEOS HD (9th) (1379-5076)
*The calendar above is tentative and subject to change due to company circumstances. ---------------------------------------August 9 (Friday) <1379> Hokuto <1381> Access <1384> Hokuriyo <1414> Showbond <1417> Miraito One <1429> Japan Aqua <142A> Gingerbread <1431> Livework <14
Emerging markets stock digest: Sasmeco is rising, Mobiles temporarily hit the ceiling.
<4268> Edge Technology 509 +93 days rebound. It is well received that they have announced that they will provide an AI platform and support for AI introduction in the AI introduction project promoted by the Shiga Prefectural Government. As a certain introduction effect was seen in the PoC phase, the generated AI submitted a prompt that can be used in the systems that Shiga Prefecture has already introduced, and will be available for use in future business. AutoML is also being developed by Shiga Prefecture staff using their own data and AI.
Sasmido --- announced the development of a therapeutic app at the oral session of the American Clinical Oncology Society Annual Meeting.
On the 5th, Sasmido <4263> announced that the "Decision Support Program for Advanced Cancer Patients," which the company is conducting joint research on, was presented at the oral session of the annual meeting of the American Society of Clinical Oncology (ASCO) held on June 2. The company aims to address the social isolation and loneliness, as well as the shortage of medical and nursing care faced by cancer survivors by conducting research and development of new education approaches and digital medical technology in collaboration with Tokyo Jikei University School of Medicine.
No Data